Effect of UGIR in Adults With Compromised Gut Function and Malabsorption

Metagenics

Status

Completed

Conditions

Irritable Bowel Syndrome

Celiac Disease

Ulcerative Colitis

Crohn Disease

Treatments

Other: Nutrition Support Product

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03011593

UGIR

Details and patient eligibility

About

This study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption.

Full description

This prospective, non-randomized, open-label study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption. Adults with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) or celiac disease were enrolled in the study and asked to take the study product for 6 weeks. The primary measure of the study was a validated quality of life questionnaire, the Gastrointestinal Quality of Life Index (GIQLI). Secondary measures included the Inflammatory Bowel Disease Questionnaire (IBDQ), the Celiac Disease Questionnaire (CDQ), and the Digestive Symptom Frequency Questionnaire (DSFQ).

Enrollment

18 patients

Sex

All

Ages

21 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Body mass index 19 - 40 kg/m2
Previous diagnosis of ulcerative colitis (UC), Crohn's disease, irritable bowel syndrome (IBS), or celiac disease

Exclusion criteria

Gastroenterologic surgery within 3 months before the study period
Have a colostomy or ileostomy bag
Malignancy within the last 5 years
Women who are lactating, pregnant or planning pregnancy during the study period
Taking antibiotic, antiparasitic, or antifungal medications
Initiation of or changes to supplements or medications within 28 days prior to screening